Core Insights - Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases [1][3] Company Overview - The company utilizes a proprietary iPSC product platform to create multiplexed-engineered master iPSC lines and manufacture off-the-shelf, iPSC-derived cell products [3] - Fate Therapeutics has established a leadership position in the clinical development of iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to deliver multiple therapeutic mechanisms [3] - The company is headquartered in San Diego, California [3] Upcoming Events - Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York [1] - Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET [1]

Core Insights - DraftKings has launched a Spanish-language experience within its Sportsbook & Casino app, reflecting the company's commitment to customer-centric services and expanding its market reach [1][2]. Group 1: Product Development - The new Spanish-language functionality aims to enhance the user experience for Spanish-speaking players, who represent a growing segment of DraftKings' customer base [2]. - This feature will be rolled out initially to select existing customers in the U.S. and Ontario, with plans for broader availability in the coming weeks [2][3]. - The Spanish-language experience will encompass the entire customer journey, including account onboarding, navigation, betting content, gameplay, promotions, customer support, and responsible gaming resources [3]. Group 2: Company Overview - DraftKings Inc. is a digital sports entertainment and gaming company founded in 2012, headquartered in Boston, offering products in daily fantasy, regulated gaming, and digital media [4]. - The company operates sports betting in 28 states, Washington, D.C., Ontario, Canada, and Puerto Rico, and provides iGaming services in five states and Ontario [4]. - DraftKings is an official partner of major sports leagues, including the NFL, NHL, PGA TOUR, WNBA, UFC, NBA, and MLB, and also owns the leading digital lottery courier app, Jackpocket [4].

Core Insights - The merger between Galaxy Gaming, Inc. and Evolution Malta Holding Limited is progressing, with Mississippi's regulatory approval secured, leaving only two jurisdictions pending approval [1][3] - The merger agreement has been extended to July 17, 2026, demonstrating both companies' commitment to completing the transaction and enhancing innovation in the gaming industry [2][4] Regulatory Approval Process - The companies expect to receive the necessary regulatory approvals in the first quarter of 2026, with Mississippi's approval already obtained in November 2025 [3] - Both companies are actively collaborating with regulators to fulfill the remaining gaming approvals by the extended deadline [3][4] Company Statements - Evolution's CEO expressed confidence in the merger's progress and emphasized the importance of Galaxy Gaming's innovative products in strengthening Evolution's market position [4] - Galaxy Gaming's CEO highlighted the merger as a significant opportunity for both companies to enhance customer experiences across various gaming channels [4] Post-Merger Strategy - After the merger, Galaxy Gaming will operate as an independent business unit within Evolution, maintaining its unique culture while benefiting from Evolution's global resources [4] - The focus will be on driving omni-channel innovation and creating additional value for partners and players worldwide [4]

Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]

Core Viewpoint - Ollie's Bargain Outlet Holdings, Inc. will report its financial results for the third quarter of fiscal 2025 on December 9, 2025, before market opening [1] Group 1: Financial Reporting - The financial results will be discussed in a conference call hosted by the President and CEO, Eric van der Valk, and the Executive Vice President and CFO, Robert Helm, at 8:30 a.m. Eastern Time on the same day [1] - Interested parties can access the live conference call by pre-registering and will receive dial-in instructions [2] Group 2: Company Overview - Ollie's is a leading off-price retailer specializing in brand name household products, operating under the mission of selling Good Stuff Cheap® since its founding in 1982 [3] - The company utilizes a flexible buying model focusing on closeout merchandise and excess inventory, offering prices up to 70% below traditional retailers [3] - As of August 2, 2025, Ollie's operates 613 stores across 34 states, with plans for further growth [3]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]

Core Insights - Catheter Precision, Inc. is positioned to expand the commercialization of its LockeT device following the recent addition of key electrophysiology (EP) ablation procedures to the ambulatory surgery centers (ASC) by the Centers for Medicare and Medicaid Services (CMS) [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias and advancing electrophysiology procedures through collaboration with physicians [5] Product Information - The LockeT device is a suture retention device designed for wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [4] Industry Impact - The addition of EP ablation codes to the ASC-Covered Procedures List (ASC-CPL) by CMS, effective January 1, 2026, significantly enhances Medicare beneficiary access to EP services, marking a major advancement in the delivery of EP care in over two decades [2] Market Opportunity - The new CMS codes will facilitate additional patient scheduling and allow for the use of LockeT in more facilities, supporting physicians and patients in post-ablation recovery while ensuring cost-effectiveness and safety [3]

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida. A live webcast of the presentation will be available in the investors section of the company’s website at www.sept ...

Topline Revenues exceed $1,250,000 for Best Quarter of 2025 SAN DIEGO, CALIFORNIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- International Land Alliance, Inc. (OTCQB:ILAL), (“ILAL” or the “Company”), a global real estate investment and development firm, announced today sales volume in excess of $1,250,000 during Q4, which is comprised primarily of land sales and construction revenue at both Rancho Costa Verde and Cabo Oasis Park. Frank Ingrande, President and CEO of ILAL, noted: “We took decisive actions to streaml ...

Core Insights - zSpace, Inc. has established a standalone AR/VR learning lab at Boca Raton Community Middle School, enhancing career exploration and student engagement for 1,000 students [1][2]. Implementation and Impact - Boca Raton Community Middle School is the first in Palm Beach County to implement a full class set of zSpace systems, providing a dedicated immersive learning environment [2]. - The zSpace lab is utilized across various subjects, allowing teachers to reinforce difficult concepts through interactive exploration [3][4]. - The integration of zSpace into after-school programs has engaged students, making learning enjoyable and interactive [5]. Career Exploration - zSpace Career Explorer enables students to simulate real-world skills and understand job responsibilities, fostering career awareness [5][6]. - Students express newfound career interests through zSpace, indicating its effectiveness in broadening their horizons [7][8]. Student Engagement - Feedback from students highlights the fun and interactive nature of zSpace, with many expressing excitement about potential careers they learned about [7][8]. - The program is seen as a tool for developing well-rounded, future-ready learners, aligning with the school's mission [8]. Company Overview - zSpace, Inc. specializes in AR/VR experiences aimed at improving engagement and outcomes in STEM and career readiness programs, trusted by over 3,500 educational institutions [10].